Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 730 |
Reported balance
After 2026-07-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-22 · Grant · Acquired 730 · Balance 730 F1: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2: In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date. F3: Not applicable as restricted stock units do not have an expiration date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 2,300 |
Reported balance
After 2026-07-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-22 · Grant · Acquired 2,300 · Balance 2,300 F2: In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
F2: In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date.
F3: Not applicable as restricted stock units do not have an expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 23, 2026 20:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Option · Derivative | 2,300 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001201252-26-000010 · primarydocument.xml · derivative · entry 2 DZAU VICTOR J · CIK 0001201252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires 2033-07-22 F2 · shares: In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 730 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001201252-26-000010 · primarydocument.xml · derivative · entry 1 DZAU VICTOR J · CIK 0001201252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730 Underlying: Common Stock · 730 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date. F3 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.